Biohaven Ltd (BHVN) Actualités

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential...

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results PR...

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of...

Form 8-K - Current report

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Po

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan...

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE...

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 7...

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest...

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent...

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity PR...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments PR Newswire NEW HAVEN...